The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
 
Nicolas Huyghe
No Relationships to Disclose
 
Astrid De Cuyper
No Relationships to Disclose
 
Isabelle Sinapi
No Relationships to Disclose
 
Fazulur Rehaman Vempalli
No Relationships to Disclose
 
Darawan Rinchai
No Relationships to Disclose
 
Simon Beyaert
No Relationships to Disclose
 
Eleonore Verstraelen
No Relationships to Disclose
 
Pierre Goffette
No Relationships to Disclose
 
Benoît Ghaye
No Relationships to Disclose
 
Mélanie Gilet
No Relationships to Disclose
 
Aline Van Maanen
No Relationships to Disclose
 
Marie-Laure Castella
No Relationships to Disclose
 
Bernhard Mlecnik
Patents, Royalties, Other Intellectual Property - INSERM
 
Javier Carrasco
No Relationships to Disclose
 
Jerome Galon
Employment - Veracyte
Leadership - HalioDx
Stock and Other Ownership Interests - Veracyte
Consulting or Advisory Role - Catalym; IO Biotech; Lunaphore Technologies; Northwest Biotherapeutics
Research Funding - Akoya Biosciences (Inst); AstraZeneca (Inst); ImCheck therapeutics (Inst); NanoString Technologies (Inst); Ultivue (Inst)
Patents, Royalties, Other Intellectual Property - INSERM (French NIH)
Travel, Accommodations, Expenses - Veracyte
 
Davide Bedognetti
No Relationships to Disclose
 
Marc Van Den Eynde
Consulting or Advisory Role - amgen (Inst); Lilly (Inst); Merck KGaA (Inst); SERVIER (Inst)
Research Funding - Merck KGaA (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); Roche (Inst)